Inside the Oral GLP-1 Supply Chain: Why Some Pills Are Easier to Get Than Others
Key Takeaways
- Oral Wegovy and Rybelsus share Novo Nordisk's manufacturing capacity — the same company that's been supply-constrained on injectable Wegovy
- Foundayo uses small-molecule synthesis (chemical manufacturing), which is generally easier to scale than peptide production
- Compounded oral GLP-1s depend on bulk semaglutide/tirzepatide API supply from raw material suppliers, which has its own constraints
- The FDA's compounding enforcement actions directly affect the availability of compounded oral formats
- Insurance formulary placement determines whether your pharmacy can even stock a given product for you
Some oral GLP-1 products are readily available; others have waitlists. The difference comes down to manufacturing chemistry, regulatory status, and distribution channels. Here's why supply varies and what it means for getting your medication.
Brand-Name Supply: Two Very Different Stories
Novo Nordisk (Oral Wegovy, Rybelsus)
Novo Nordisk manufactures semaglutide as a peptide — a complex biological process involving fermentation, purification, and formulation with SNAC. The company has struggled with supply constraints on injectable Wegovy and Ozempic since 2022. Oral Wegovy uses the same active ingredient, adding another demand stream on the same manufacturing base.
The result: oral Wegovy availability varies by region and dose strength. The NovoCare self-pay program has helped manage demand by routing patients directly, but pharmacy stock for insurance-covered prescriptions can be inconsistent.
Eli Lilly (Foundayo)
Orforglipron is a small molecule — manufactured through chemical synthesis rather than biological fermentation. Chemical synthesis is generally faster to scale, uses more standardized equipment, and has more predictable yields. Eli Lilly has invested heavily in small-molecule manufacturing capacity, and early indications suggest Foundayo supply is more stable than Novo Nordisk's peptide products.
This manufacturing advantage is part of why Lilly pursued a small-molecule GLP-1 in the first place — not just for patient convenience, but for supply-chain reliability.
Compounded Supply: API and Regulatory Factors
Compounded oral GLP-1s (troches, sublingual, tablets) depend on two things:
- Bulk API (active pharmaceutical ingredient) availability — compounding pharmacies buy raw semaglutide or tirzepatide powder from API suppliers. When demand surges or a major supplier has issues, prices rise and availability tightens.
- FDA enforcement posture — the FDA's position on compounded GLP-1s has tightened through 2025–2026. When Novo Nordisk's semaglutide came off the FDA drug shortage list, some compounding pharmacies faced legal challenges to their right to compound it. This creates periods of uncertainty where some providers temporarily pause or limit offerings.
Telos Rx
Oral TirzepatideCompounded oral tirzepatide via Telos Rx. First-month pricing starts at $40; ongoing pricing varies by plan length ($160–249/mo).
MadeMed
Oral SemaglutideCompounded oral semaglutide in tablet form. Quarterly plan brings cost to $89/month; monthly refill is $119/month.
What This Means for Patients
If supply reliability is your priority: Foundayo (small-molecule, easier to manufacture) and brand-name products purchased through manufacturer programs (NovoCare, LillyDirect) generally have the most reliable supply.
If price is your priority: Compounded providers offer lower prices but with more supply variability. Having a backup provider is prudent — if one compounding pharmacy has supply issues, another may not.
For all formats: Order refills 1–2 weeks before you run out, not the day of. Supply disruptions are more manageable with a buffer.
The oral GLP-1 supply picture in 2026 is better than the injectable supply picture was in 2023–2024, largely because small-molecule manufacturing (Foundayo) scales more easily than peptide production. But compounded supply remains vulnerable to both API availability and FDA enforcement. Diversifying your awareness of available providers — brand-name and compounded — gives you the most options if any single channel experiences disruption.
Supply chain information current as of July 2026. Availability varies by region and provider. Consult your pharmacy or telehealth provider about current stock.